期刊
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.749490
关键词
DNA damage response (DDR); pancreatic duct adenocarcinoma (PDAC); preclinical model; cell line; organoid; genetically engineered mouse model (GEMM); xenograft; targeted therapy
资金
- EU Horizon-2020 Program PancREatic Cancer OrganoiDs rEsearch Network [861196]
- Pancreatic Cancer Research Fund (award round 2018)
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with DDR deficiency playing an important role in its pathogenesis, yet understanding of these mechanisms is limited. The lack of appropriate laboratory experimental models poses a challenge to preclinical research, despite the potential for high predictivity and effective clinical translation when models effectively recapitulate the original cancer.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and survival rates have barely improved in decades. In the era of precision medicine, treatment strategies tailored to disease mutations have revolutionized cancer therapy. Next generation sequencing has found that up to a third of all PDAC tumors contain deleterious mutations in DNA damage repair (DDR) genes, highlighting the importance of these genes in PDAC. The mechanisms by which DDR gene mutations promote tumorigenesis, therapeutic response, and subsequent resistance are still not fully understood. Therefore, an opportunity exists to elucidate these processes and to uncover relevant therapeutic drug combinations and strategies to target DDR deficiency in PDAC. However, a constraint to preclinical research is due to limitations in appropriate laboratory experimental models. Models that effectively recapitulate their original cancer tend to provide high levels of predictivity and effective translation of preclinical findings to the clinic. In this review, we outline the occurrence and role of DDR deficiency in PDAC and provide an overview of clinical trials that target these pathways and the preclinical models such as 2D cell lines, 3D organoids and mouse models [genetically engineered mouse model (GEMM), and patient-derived xenograft (PDX)] used in PDAC DDR deficiency research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据